Literature DB >> 26796671

Salient Features of Endonuclease Platforms for Therapeutic Genome Editing.

Michael T Certo1, Richard A Morgan1.   

Abstract

Emerging gene-editing technologies are nearing a revolutionary phase in genetic medicine: precisely modifying or repairing causal genetic defects. This may include any number of DNA sequence manipulations, such as knocking out a deleterious gene, introducing a particular mutation, or directly repairing a defective sequence by site-specific recombination. All of these edits can currently be achieved via programmable rare-cutting endonucleases to create targeted DNA breaks that can engage and exploit endogenous DNA repair pathways to impart site-specific genetic changes. Over the past decade, several distinct technologies for introducing site-specific DNA breaks have been developed, yet the different biological origins of these gene-editing technologies bring along inherent differences in parameters that impact clinical implementation. This review aims to provide an accessible overview of the various endonuclease-based gene-editing platforms, highlighting the strengths and weakness of each with respect to therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26796671      PMCID: PMC4786926          DOI: 10.1038/mt.2016.21

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  132 in total

Review 1.  Homing endonucleases: structure, function and evolution.

Authors:  M S Jurica; B L Stoddard
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 3.  Homing endonuclease structure and function.

Authors:  Barry L Stoddard
Journal:  Q Rev Biophys       Date:  2005-12-09       Impact factor: 5.318

Review 4.  Regulation of DNA repair throughout the cell cycle.

Authors:  Dana Branzei; Marco Foiani
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02-20       Impact factor: 94.444

Review 5.  Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.

Authors:  Jennifer L Gori; Patrick D Hsu; Morgan L Maeder; Shen Shen; G Grant Welstead; David Bumcrot
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

6.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Authors:  Ayal Hendel; Rasmus O Bak; Joseph T Clark; Andrew B Kennedy; Daniel E Ryan; Subhadeep Roy; Israel Steinfeld; Benjamin D Lunstad; Robert J Kaiser; Alec B Wilkens; Rosa Bacchetta; Anya Tsalenko; Douglas Dellinger; Laurakay Bruhn; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2015-06-29       Impact factor: 54.908

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  Limiting the persistence of a chromosome break diminishes its mutagenic potential.

Authors:  Nicole Bennardo; Amanda Gunn; Anita Cheng; Paul Hasty; Jeremy M Stark
Journal:  PLoS Genet       Date:  2009-10-16       Impact factor: 5.917

9.  High frequency targeted mutagenesis using engineered endonucleases and DNA-end processing enzymes.

Authors:  Fabien Delacôte; Christophe Perez; Valérie Guyot; Marianne Duhamel; Christelle Rochon; Nathalie Ollivier; Rachel Macmaster; George H Silva; Frédéric Pâques; Fayza Daboussi; Philippe Duchateau
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

10.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.

Authors:  Sandrine Boissel; Jordan Jarjour; Alexander Astrakhan; Andrew Adey; Agnès Gouble; Philippe Duchateau; Jay Shendure; Barry L Stoddard; Michael T Certo; David Baker; Andrew M Scharenberg
Journal:  Nucleic Acids Res       Date:  2013-11-26       Impact factor: 16.971

View more
  6 in total

1.  Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing.

Authors:  Eric D Austin; James West; James E Loyd; Anna R Hemnes
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

2.  Genome Editing in Large Animals.

Authors:  James West; W Warren Gill
Journal:  J Equine Vet Sci       Date:  2016-03-25       Impact factor: 1.583

Review 3.  Advances in genome editing for improved animal breeding: A review.

Authors:  Shakil Ahmad Bhat; Abrar Ahad Malik; Syed Mudasir Ahmad; Riaz Ahmad Shah; Nazir Ahmad Ganai; Syed Shanaz Shafi; Nadeem Shabir
Journal:  Vet World       Date:  2017-11-21

Review 4.  Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Authors:  Jan A Rath; Caroline Arber
Journal:  Cells       Date:  2020-06-18       Impact factor: 6.600

5.  Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing.

Authors:  Arnold Park; Patrick Hong; Sohui T Won; Patricia A Thibault; Frederic Vigant; Kasopefoluwa Y Oguntuyo; Justin D Taft; Benhur Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-24       Impact factor: 6.698

6.  AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines.

Authors:  Liyang Zhang; John A Zuris; Ramya Viswanathan; Jasmine N Edelstein; Rolf Turk; Bernice Thommandru; H Tomas Rube; Steve E Glenn; Michael A Collingwood; Nicole M Bode; Sarah F Beaudoin; Swarali Lele; Sean N Scott; Kevin M Wasko; Steven Sexton; Christopher M Borges; Mollie S Schubert; Gavin L Kurgan; Matthew S McNeill; Cecilia A Fernandez; Vic E Myer; Richard A Morgan; Mark A Behlke; Christopher A Vakulskas
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.